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Letters to the Editor
Endothelial Function
in Coronary Chronic
Total Occlusions
Need for Rigorous Methodology
We read with interest the paper by Galassi et al. (1). We agree with
the authors about the fact that immediately after chronic total
occlusion (CTO) recanalization, there is an impairment of
endothelium-dependent and -independent vasomotion, as also dem-
onstrated in recent studies (2,3). However, some limitations and flaws
in the methodology and in the results presentation need to be
highlighted and clarified by the authors.
With regard to quantitative coronary angiography (QCA), it is
of value to use 3-dimensional QCA (3D-QCA), which is known
to overcome the limitations of 2-dimensional QCA (2D-QCA),
such as foreshortening, thus making the measurements more
reliable (4). However, it is quite unusual and arbitrary that the
authors measured only the reference vessel diameter (RVD) or that
such measurement was not performed in a coronary segment, but
at 3 single points distal to the stent edge. All previous studies
classically quantified the vasomotion in a coronary segment,
reporting the changes in mean lumen diameter and not in RVD
(5,6). The restriction of the analysis to 3 single QCA points limits
the observation, multiplying the measurements per patients and
not taking into account any data clustering. Moreover, in contrast
to what is reported in the Results section, Table 3 shows the
intravascular ultrasound (IVUS) data and not the QCA data of the
vasomotion substudy.
The coronary segment distal to the CTO was also analyzed by
IVUS. The authors again decided to restrict the observation,
performing the analysis every 5 mm, instead of the conventionally
used 1 mm. Although it is known that the 3D-QCA measure-
ments are closer to the IVUS measurements compared with
2D-QCA, it is noteworthy that in the present study, there was not
an increase in lumen diameter by IVUS in contrast to QCA (7). It
may have to do with the fact that the QCA points do not match
the sampling of IVUS. Nevertheless, this contradictory message
(QCA vs. IVUS) makes their observations much less solid: in the
best scenario, IVUS is much more reliable to quantify lumen
dimensions than QCA and therefore the main conclusion of the
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August 28, 2012:869–74paper should be that there is no increase in lumen dimensions as
seen by IVUS.
In addition to this, the IVUS data reported in the table partially
differ from those reported in the text and includes the measure-
ment of intimal hyperplasia in the coronary segment distal to the
recanalized CTO, where no stent was implanted and no intimal
hyperplasia could therefore be measured (8).
Finally, the authors underestimated the role of the drug-eluting
tent (DES)–dependent endothelial dysfunction, which is nor-
ally present in the coronary segment distal to a first-generation
ES, caused by the downstream elution of the antiproliferative
rug and that has disappeared with the introduction of second-
eneration DES (5). As the vasomotion substudy included only
atients with first-generation DESs, the persistence or the wors-
ning of the endothelial dysfunction at follow-up distal to the stent
reviously implanted could be first-generation DES-related and
ot deriving from a long-acting endothelial dysfunction of the
oronary segment distal the CTO after recanalization.
Based on these concerns, most of the findings of the present
tudy should be taken as hypothesis generating and would need
urther investigation in a well-designed and powered study.
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Reply
We thank Dr. Brugaletta and colleagues for their valuable com-
ments on our paper (1).
First, as they point out, 3-dimensional quantitative coronary
angiography (3D-QCA) might overcome several limitations of
2-dimensional (2D-QCA), as previously shown also in our previ-
ous experience (2). We concur that it is unusual to select as the
primary measurement the reference vessel diameter (RVD) instead
of minimal lumen diameter in this kind of investigation. We made
this decision because it was unknown at the beginning of the study
whether changes in the vessel caliper would be ascribed to coronary
vasomotion or to a remodeling phenomenon. Moreover, we
disagree that measuring 3 single QCA points might limit the study
results. Indeed, with this method, we were able to provide coronary
measurements at a certain point and reproduce them at follow-up,
further assessing the relationship between vessel diameter mea-
surement and its percentage of variation.
Second, differently from the standards (3), we decided to
erform intravascular ultrasound (IVUS) analysis every 5 mm,
onsidering the very long coronary segments assessed. Thus, we
ere able to limit the bias related to data clustering. Notably, with
uch analysis, it was easier to reproduce measurements at follow-
p. We probably did not observe any changes in IVUS measure-
ents because of the small sample size of the IVUS substudy,
hich was not sufficiently powered to show any significant differ-
nce. In this regard, we would like to emphasize that the primary
ndpoint of the main analysis was the RVD at angiographic
ollow-up as assessed by 3D-QCA, and for this evaluation, an
ppropriate pre-specified sample size was used.
Third, we truly concur with Dr. Brugaletta and colleagues
egarding the possibility that because the vasomotion substudy
ncluded only patients receiving first-generation drug-eluting
tents (DESs), the persistence or worsening of the endothelial
ysfunction at follow-up distal to the implanted stent could be
rst-generation DES related and not caused by a long-acting
ndothelial dysfunction of the coronary segment distal to the CTO
fter recanalization. This is a limitation that was discussed in the
ext.
Fourth, we apologize to the editor and readers for some typing
nd spelling errors in the Results section, which did not substan-
ially affect the study conclusions.
Finally, we believe that our study clearly shows that recanaliza-
ion of CTO is followed by a reversible hibernation of the vascular
all at distal coronary segments, which determine an increase in
essel diameter on long-term follow-up due to an increase in shear
tress. We hope that using our findings as hypothesis generating,
uture sufficiently powered investigations will provide a better
xplanation of this phenomenon.
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